All Posts
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.
Published: February 24th, 2015
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Published: February 24th, 2015
The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study.
Published: February 24th, 2015
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.
Published: February 24th, 2015
Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study.
Published: February 24th, 2015
Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension.
Published: February 24th, 2015
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
Published: February 24th, 2015
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Published: February 24th, 2015
RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment.
Published: February 24th, 2015
Pharmacogenetic effects of ‘candidate gene complexes’ on stroke in the GenHAT study.
Published: February 24th, 2015